Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management

Boulate,Geoffrey; Amazit,Larbi; Naman,Annabelle; Seck,Atmane; Paci,Angelo; Lombes,Anne; Pussard,Eric; Baudin,Eric; Lombes,Marc; Hescot,Ségolène

doi:10.3892/ijo.2019.4770

Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management

Authors:
- Geoffrey Boulate
- Larbi Amazit
- Annabelle Naman
- Atmane Seck
- Angelo Paci
- Anne Lombes
- Eric Pussard
- Eric Baudin
- Marc Lombes
- Ségolène Hescot
View Affiliations

Affiliations: INSERM UMR‑S 1185, 94276 Le Kremlin‑Bicêtre Cedex, France, Department of Pharmacology, Gustave Roussy, 94800 Villejuif, France, INSERM UMRS 1016, Cochin Institute, 75014 Paris, France, Department of Genetics and Hormonology, APHP, 94270 Le Kremlin‑Bicêtre Cedex, France
Published online on: April 3, 2019 https://doi.org/10.3892/ijo.2019.4770
Pages: 2149-2156

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitotane (also termed o,p'‑DDD) is the most effective therapy for advanced adrenocortical carcinoma (ACC). Mitotane‑induced dyslipidemia is treated with statins. Mitotane and statins are known to exert anti‑proliferative effects in vitro; however, the effects of statins have never been directly evaluated in patients with ACC and ACC cells, at least to the best of our knowledge. Thus, in this study, we aimed to examine the effects of the rosuvastatin on ACC cells. It has been shown that the combined use of mitotane and statins significantly increases the tumor control rate in patients with ACC; however, it would be of interest to elucidate the molecular mechanisms involved in this potentiation. In this study, we examined the effects of mitotane, rosuvastatin and their combination in NCI‑H295R human ACC cells using proliferation assays, gene expression analyses and free intracellular cholesterol measurements. The results revealed that mitotane dose‑dependently reduced cell viability, induced apoptosis and increased intracellular free cholesterol levels, considered as one of the key features of mitotane action, while rosuvastatin alone reduced cell viability and increased apoptosis at high concentrations. We also demonstrated that rosuvastatin potentiated the effects of mitotane by reducing cell viability, inducing apoptosis, increasing intracellular free cholesterol levels, and by decreasing the expression of 3‑hydroxy‑3‑methylglutaryl‑CoA reductase (HMGCR) and ATP binding cassette subfamily a member 1 (ABCA1), genes involved in cholesterol metabolism, and inhibiting steroidogenesis. Collectively, potentiating the effects of mitotane with the use of rosuvastatin may provide novel therapeutic strategies for ACC, given that the combination of these drugs, pending clinical validation, may lead to the better management of ACC.

View Figures

View References

1	Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F and Fassnacht M: Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23(Suppl 7): vii131–vii138. 2012. View Article : Google Scholar : PubMed/NCBI
2	Hescot S, Slama A, Lombès A, Paci A, Remy H, Leboulleux S, Chadarevian R, Trabado S, Amazit L, Young J, et al: Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer. 20:371–381. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hescot S, Seck A, Guerin M, Cockenpot F, Huby T, Broutin S, Young J, Paci A, Baudin E and Lombès M: Lipoprotein-free mitotane exerts high cytotoxic activity in adrenocortical carcinoma. J Clin Endocrinol Metab. 100:2890–2898. 2015. View Article : Google Scholar : PubMed/NCBI
4	Hescot S, Amazit L, Lhomme M, Travers S, DuBow A, Battini S, Boulate G, Namer IJ, Lombes A, Kontush A, et al: Identifying mitotane-induced mitochondria-associated membranes dysfunctions: Metabolomic and lipidomic approaches. Oncotarget. 8:109924–109940. 2017. View Article : Google Scholar
5	Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, et al: Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 156:3895–3908. 2015. View Article : Google Scholar : PubMed/NCBI
6	Shawa H, Deniz F, Bazerbashi H, Hernandez M, Vassilopoulou-Sellin R, Jimenez C and Habra MA: Mitotane-induced hyper-lipidemia: A retrospective cohort study. Int J Endocrinol. 2013:6249622013. View Article : Google Scholar
7	Paci A, Hescot S, Seck A, Jublanc C, Mercier L, Vezzosi D, Drui D, Quinkler M, Fassnacht M, Bruckert E, et al: Dyslipidemia causes overestimation of plasma mitotane measurements. Endocrinol Diabetes Metab Case Rep. 2016:1501352016.PubMed/NCBI
8	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
9	Pisanti S, Picardi P, Ciaglia E, D’Alessandro A and Bifulco M: Novel prospects of statins as therapeutic agents in cancer. Pharmacol Res. 88:84–98. 2014. View Article : Google Scholar : PubMed/NCBI
10	Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem R, Jurisica I, et al: Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA. 107:15051–15056. 2010. View Article : Google Scholar : PubMed/NCBI
11	Hescot S, Paci A, Seck A, Slama A, Viengchareun S, Trabado S, Brailly-Tabard S, Al Ghuzlan A, Young J, Baudin E, et al: The lack of antitumor effects of o,p′DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment. Horm Cancer. 5:312–323. 2014. View Article : Google Scholar : PubMed/NCBI
12	Takeshita A, Igarashi-Migitaka J, Koibuchi N and Takeuchi Y: Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. J Endocrinol. 216:297–305. 2013. View Article : Google Scholar
13	Touitou Y, Moolenaar AJ, Bogdan A, Auzéby A and Luton JP: o,p′-DDD (mitotane) treatment for Cushing’s syndrome: Adrenal drug concentration and inhibition in vitro of steroid synthesis. Eur J Clin Pharmacol. 29:483–487. 1985. View Article : Google Scholar
14	Burns VE and Kerppola TK: ATR-101 inhibits cholesterol efflux and cortisol secretion by ATP-binding cassette transporters, causing cytotoxic cholesterol accumulation in adrenocortical carcinoma cells. Br J Pharmacol. 174:3315–3332. 2017. View Article : Google Scholar : PubMed/NCBI
15	LaPensee CR, Mann JE, Rainey WE, Crudo V, Hunt SW III and Hammer GD: ATR-101, a selective and potent inhibitor of Acyl-CoA acyltransferase 1, induces apoptosis in H295R adre-nocortical cells and in the adrenal cortex of dogs. Endocrinology. 157:1775–1788. 2016. View Article : Google Scholar : PubMed/NCBI
16	U.S National Library of Medicine: A Study of ATR-101 for the Treatment of Endogenous Cushing’s Syndrome. (Identification No. NCT03053271). https://clinicaltrials.gov/ct2/show/NCT03053271 Accessed February 15, 2019.
17	Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati IS, Fogal V, Pastorino S, Teng D, Cong X, Pingle SC, et al: In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer. 111:1562–1571. 2014. View Article : Google Scholar : PubMed/NCBI
18	Guldvang A, Hansen CH, Weisser JJ, Halling-Sørensen B and Styrishave B: Simvastatin decreases steroid production in the H295R cell line and decreases steroids and FSH in female rats. Reprod Toxicol. 58:174–183. 2015. View Article : Google Scholar : PubMed/NCBI